All trials that explore the efficacy of PARPi in high-penetrance risk genes (BRCA1/2, PALB2) have shown activity in those genes, definitely introducing in the metastatic breast cancer therapeutic algorithm a new standard treatment for germline mutation carriers. This evidence concerns the gene BRCA1 and breast cancer.